Monoclonal antibodies that target pathological assemblies of amyloid β (Abeta)

US8507206B2 · kind B2 · utility

Assignees

• Northwestern University · US
• Acumen Pharmaceuticals, Inc. · US

Inventors

• Mary P. Lambert · Glenview, US
• Pauline T. Velasco · Wilmette, US
• Lei Chang · Heverlee, BE
• Kirsten L. Viola · Lake Forest, US
• Sara J. Fernandez · Chicago, US
• Pascale N. Lacor · Chicago, US
• Daliya Khuon · Chicago, US
• Yuesong Gong · Evanston, US
• William L. Klein · Nutley, US
• Grant A. Krafft · Glenview, US

Key dates

• Filing date: Jul 5, 2005
• Grant date: Aug 13, 2013
• Expiry date: Apr 24, 2029

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2800/2821
• WIPO field: Measurement
• WIPO sector: Instruments

Abstract

Disclosed herein are antibodies that bind with high specificity to soluble oligomers of amyloid β (Abeta) and methods of employing those antibodies. The antibodies are able to distinguish between Alzheimer's Disease (AD) and control human brain extracts. The antibodies identify endogenous Abeta oligomers in AD brain slices and also bind to Abeta oligomers on cultured hippocampal cells. The antibodies neutralize endogenous Abeta oligomers and Abeta oligomers produced in solution.